drugset
drugset / Trial / NCT04913337

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NCT04913337 ↗

Phase 1/2 Unknown 179 enrolled NGM Biopharmaceuticals, Inc Merck Sharp & Dohme LLC · collab
Non-randomizedFactorialOpen-labelTreatment

Summary

Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Timeline

Start
2021-06-09
Primary completion
2025-02
Completion
2025-07

Drugs

EvaluationDrugModalityDoseRoute
Subject NGM707 Unknown — Intravenous
Background Pembrolizumab Monoclonal antibody — Intravenous

Indications

breast cancer cholangiocarcinoma colorectal cancer endocervical carcinoma esophageal cancer gastric cancer glioblastoma head and neck squamous cell carcinoma melanoma mesothelioma non-small cell lung carcinoma ovarian cancer pancreatic ductal adenocarcinoma renal cell carcinoma